Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cintas Corporation (CTAS) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance

Cintas CorporationTrade
Cognizant Technology Solutions CorpTrade

Price performance (Past 24H)

Key statistics

Cintas Corporation vs Cognizant Technology Solutions Corp — how do they compare? Cintas Corporation trades at $201.95 (market cap $79.86B), while Cognizant Technology Solutions Corp trades at $59.27 (market cap $27.03B). The key difference: Cintas Corporation is far larger — about 3× Cognizant Technology Solutions Corp's market cap, and Cognizant Technology Solutions Corp pays the higher dividend (2.2%). Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Cognizant Technology Solutions Corp for 57 Days on average.

CTASCTSH
Market Cap
$79.86B$27.03B
Volume
1,323,5839,883,888
Sector
IndustrialsTechnology
52-Week High
$216.53$86.70
52-Week Low
$163.55$38.73
Typical Hold Time
124 Days57 Days
Enterprise Value
$82.33B$28.08B
Dividend Yield
1.03%2.2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cintas Corporation

Cintas (CTAS) trades at $201.87, up 2.37% today, reflecting strong momentum after Q1 2027 earnings beat. The stock shows bullish technical signals with support near $195 and resistance at $200. Fundamentals are robust with revenue growth to $10.34B in 2025, net margin of 17.82%, and rising profitability. Recent news highlights raised guidance and record quarterly revenue exceeding $3B, signaling operational strength.

Outlook remains positive driven by organic growth and margin expansion, but high valuation multiples (P/E 39.67) pose a risk if growth slows. Analyst consensus is Moderate Buy with a $234.60 price target, implying 16% upside. Key risks include economic sensitivity and competitive pressures in uniform services.

Cognizant Technology Solutions Corp

Cognizant Technology Solutions (CTSH) trades at $57.07, down 0.26% on the day, with a bearish technical signal from moving averages. The company reported revenue of $21.11B in 2025 with a net income margin of 10.26%, and recent quarterly earnings have mostly beaten expectations. Analysts maintain a consensus price target of $64.25, with 45.1% recommending a buy. Positive news includes AI partnerships and workplace recognitions, but cash flow trends show volatility.

CTSH presents a mixed outlook: undervalued fundamentals with a P/E of 12.88 and strong profitability support upside potential, but technical weakness and competitive IT spending pressures pose risks. The stock's performance hinges on Q3 2026 earnings results due October 29, 2026, which could validate AI-driven growth initiatives or exacerbate bearish sentiment.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CTAS
100% Buy0% Sell
Avg holding period · 124 Days
CTSH
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Cintas Corporation

In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).

Read more on CTAS →

About Cognizant Technology Solutions Corp

Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.

Read more on CTSH →